Arthritis Rheumatoid
📧 Sign up to get email alerts when something new happens for Arthritis Rheumatoid.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2021-01-29EMA Withdrawn: Halimatoz (adalimumab) — Sandoz GmbH
The EMA withdrew Halimatoz (adalimumab) supplied by Sandoz GmbH from the market.
-
EMA withdrawal · 2020-06-24EMA Application withdrawn: Rituximab Mabion (rituximab) — Mabion Spolka Akcyjna
The EMA application for Rituximab Mabion (rituximab) by Mabion Spolka Akcyjna has been withdrawn.
-
EMA withdrawal · 2020-03-25EMA Withdrawn: Kromeya (adalimumab) — Fresenius Kabi Deutschland GmbH
EMA has withdrawn Kromeya (adalimumab) from Fresenius Kabi Deutschland GmbH, effective 2019, affecting multiple inflammatory diseases.